GLUE
Price
$5.20
Change
+$0.02 (+0.39%)
Updated
May 17, 6:59 PM EST
82 days until earnings call
NVAX
Price
$12.99
Change
-$1.41 (-9.79%)
Updated
May 17, 6:59 PM EST
80 days until earnings call
Ad is loading...

GLUE vs NVAX

Header iconGLUE vs NVAX Comparison
Open Charts GLUE vs NVAXBanner chart's image
Monte Rosa Therapeutics
Price$5.20
Change+$0.02 (+0.39%)
Volume$78.89K
CapitalizationN/A
Novavax
Price$12.99
Change-$1.41 (-9.79%)
Volume$9.11M
CapitalizationN/A
View a ticker or compare two or three
GLUE vs NVAX Comparison Chart

Loading...

GLUEDaily Signal changed days agoGain/Loss if shorted
 
Show more...
NVAXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
GLUE vs. NVAX commentary
May 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GLUE is a Hold and NVAX is a Buy.

COMPARISON
Comparison
May 19, 2024
Stock price -- (GLUE: $5.20 vs. NVAX: $13.01)
Brand notoriety: GLUE: Not notable vs. NVAX: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GLUE: 90% vs. NVAX: 113%
Market capitalization -- GLUE: $262.66M vs. NVAX: $1.92B
GLUE [@Biotechnology] is valued at $262.66M. NVAX’s [@Biotechnology] market capitalization is $1.92B. The market cap for tickers in the [@Biotechnology] industry ranges from $593.52B to $0. The average market capitalization across the [@Biotechnology] industry is $2.75B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GLUE’s FA Score shows that 0 FA rating(s) are green whileNVAX’s FA Score has 0 green FA rating(s).

  • GLUE’s FA Score: 0 green, 5 red.
  • NVAX’s FA Score: 0 green, 5 red.
According to our system of comparison, NVAX is a better buy in the long-term than GLUE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GLUE’s TA Score shows that 5 TA indicator(s) are bullish while NVAX’s TA Score has 6 bullish TA indicator(s).

  • GLUE’s TA Score: 5 bullish, 5 bearish.
  • NVAX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, NVAX is a better buy in the short-term than GLUE.

Price Growth

GLUE (@Biotechnology) experienced а +7.22% price change this week, while NVAX (@Biotechnology) price change was +46.51% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.41%. For the same industry, the average monthly price growth was +2.86%, and the average quarterly price growth was +60.72%.

Reported Earning Dates

GLUE is expected to report earnings on Aug 08, 2024.

NVAX is expected to report earnings on Aug 06, 2024.

Industries' Descriptions

@Biotechnology (+1.41% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for GLUE with price predictions.
OPEN
A.I.dvisor published
a Summary for NVAX with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
NVAX($1.92B) has a higher market cap than GLUE($263M). NVAX YTD gains are higher at: 171.042 vs. GLUE (-7.965).
GLUENVAXGLUE / NVAX
Capitalization263M1.92B14%
EBITDAN/AN/A-
Gain YTD-7.965171.042-5%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
NVAX: Fundamental Ratings
NVAX
OUTLOOK RATING
1..100
34
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
PROFIT vs RISK RATING
1..100
97
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
34
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
GLUENVAX
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
87%
MACD
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 4 days ago
87%
Bullish Trend 6 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 11 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Ad is loading...
GLUEDaily Signal changed days agoGain/Loss if shorted
 
Show more...
NVAXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VITNX90.910.11
+0.12%
Vanguard Instl Ttl Stk Mkt Idx I
FIUIX30.790.02
+0.07%
Fidelity Telecom and Utilities
WCMSX20.730.01
+0.05%
WCM International Small Cap Growth Instl
BRKAX14.03N/A
N/A
MFS Blended Research Em Mkts Eq A
GAHPX23.66N/A
N/A
Goldman Sachs Emerging Markets Eq P

GLUE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLUE has been loosely correlated with MDGL. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if GLUE jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLUE
1D Price
Change %
GLUE100%
-0.38%
MDGL - GLUE
47%
Loosely correlated
+1.33%
NRIX - GLUE
46%
Loosely correlated
+7.73%
XNCR - GLUE
42%
Loosely correlated
+2.54%
ERAS - GLUE
41%
Loosely correlated
+6.49%
NTLA - GLUE
38%
Loosely correlated
+0.19%
More

NVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with ADMA. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then ADMA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVAX
1D Price
Change %
NVAX100%
-9.65%
ADMA - NVAX
44%
Loosely correlated
+1.66%
THRD - NVAX
42%
Loosely correlated
-2.57%
ITOS - NVAX
41%
Loosely correlated
+0.84%
SYRE - NVAX
38%
Loosely correlated
N/A
CRSP - NVAX
35%
Loosely correlated
+0.99%
More